QCG
ACOR

Quadrant Capital Group’s Acorda Therapeutics ACOR Stock Holding History

Quadrant Capital Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1
Closed – – 2420
2019
Q2 		$0 Buy
+1
New +$1.23K ﹤0.01% 2427
2018
Q2 		– Sell
-1
Closed – – 2232
2018
Q1 		$0 Buy
+1
New +$2.99K ﹤0.01% 2239
2017
Q2 		– Sell
-1
Closed -$1K – 2113
2017
Q1 		$1K Hold
1
– – ﹤0.01% 1934
2016
Q4 		$1K Buy
+1
New +$2.38K ﹤0.01% 1861
2016
Q3 		– Hold
0
– – – 2095
2016
Q2 		– Sell
-2
Closed -$6.5K – 2101
2016
Q1 		$4K Buy
+2
New +$8.3K ﹤0.01% 1246

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quadrant Capital Group's ACOR Position: Q3 2019 in Review

Quadrant Capital Group sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 1 share.

Quadrant Capital Group first reported a position in ACOR in Q1 2016 and held it in 5 quarters. The position peaked at $4K in Q1 2016. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • Quadrant Capital Group reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Quadrant Capital Group sold 1 Acorda Therapeutics share in Q3 2019.
  • Quadrant Capital Group first reported a position in Acorda Therapeutics in Q1 2016 and held it in 5 quarters.
  • Quadrant Capital Group's Acorda Therapeutics position peaked at $4K in Q1 2016.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Quadrant Capital Group's 13F filing for Q3 2019, filed 24 Oct 2019.